ZA200701826B - Furamate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl] amino]-2-pyrimidinyl]amino]benzonitrile - Google Patents
Furamate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl] amino]-2-pyrimidinyl]amino]benzonitrile Download PDFInfo
- Publication number
- ZA200701826B ZA200701826B ZA200701826A ZA200701826A ZA200701826B ZA 200701826 B ZA200701826 B ZA 200701826B ZA 200701826 A ZA200701826 A ZA 200701826A ZA 200701826 A ZA200701826 A ZA 200701826A ZA 200701826 B ZA200701826 B ZA 200701826B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- pharmaceutical composition
- composition according
- formula
- amino
- Prior art date
Links
- YIBOMRUWOWDFLG-UHFFFAOYSA-N 4-[[4-[4-(2-cyanoethenyl)-2,6-dimethylanilino]pyrimidin-2-yl]amino]benzonitrile Chemical compound CC1=CC(C=CC#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 59
- 239000000203 mixture Substances 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 15
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 9
- 150000001204 N-oxides Chemical class 0.000 claims description 8
- 208000031886 HIV Infections Diseases 0.000 claims description 7
- 239000012458 free base Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 208000037357 HIV infectious disease Diseases 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000000080 wetting agent Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 claims 4
- 238000002156 mixing Methods 0.000 claims 3
- 239000007884 disintegrant Substances 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 1
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 28
- 241000725303 Human immunodeficiency virus Species 0.000 description 17
- 150000003839 salts Chemical class 0.000 description 14
- 229940079593 drug Drugs 0.000 description 8
- 230000035699 permeability Effects 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- -1 (4— (2-CYANOETHENYL) -2, 6-DIMETHYLPHENYL) AMINO Chemical class 0.000 description 4
- 206010001513 AIDS related complex Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 4
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000008771 Lymphadenopathy Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 230000000798 anti-retroviral effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000004209 confusion Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010013395 disorientation Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004544 spot-on Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MYPI20043578A MY169670A (en) | 2003-09-03 | 2004-09-02 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200701826B true ZA200701826B (en) | 2008-07-30 |
Family
ID=38137294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200701826A ZA200701826B (en) | 2004-09-02 | 2007-03-01 | Furamate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl] amino]-2-pyrimidinyl]amino]benzonitrile |
Country Status (6)
| Country | Link |
|---|---|
| CN (2) | CN101068597B (ru) |
| AP (1) | AP2296A (ru) |
| CR (1) | CR9031A (ru) |
| SG (1) | SG155885A1 (ru) |
| UA (2) | UA92469C2 (ru) |
| ZA (1) | ZA200701826B (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103420920B (zh) * | 2012-05-14 | 2016-04-27 | 上海迪赛诺药业有限公司 | 利匹韦林盐酸盐醇化物多晶型物及其制备方法 |
| WO2013170421A1 (zh) * | 2012-05-14 | 2013-11-21 | 上海迪赛诺药业有限公司 | 利匹韦林盐酸盐醇化物多晶型物及其制备方法 |
| CN110191704A (zh) * | 2016-10-24 | 2019-08-30 | 爱尔兰詹森科学公司 | 可分散组合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY169670A (en) * | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| CA2686429C (en) * | 2002-08-09 | 2010-11-16 | Janssen Pharmaceutica N.V. | Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
-
2005
- 2005-09-02 UA UAA200702178A patent/UA92469C2/ru unknown
- 2005-09-02 CN CN2005800380936A patent/CN101068597B/zh not_active Expired - Lifetime
- 2005-09-02 UA UAA200701971A patent/UA92467C2/ru unknown
- 2005-09-02 CN CNA200580038025XA patent/CN101056673A/zh active Pending
- 2005-09-02 SG SG200905799-3A patent/SG155885A1/en unknown
- 2005-09-02 AP AP2007003934A patent/AP2296A/xx active
-
2007
- 2007-03-01 ZA ZA200701826A patent/ZA200701826B/en unknown
- 2007-03-30 CR CR9031A patent/CR9031A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AP2007003934A0 (en) | 2007-04-30 |
| UA92467C2 (ru) | 2010-11-10 |
| CN101056673A (zh) | 2007-10-17 |
| CN101068597A (zh) | 2007-11-07 |
| UA92469C2 (en) | 2010-11-10 |
| SG155885A1 (en) | 2009-10-29 |
| AP2296A (en) | 2011-10-31 |
| CN101068597B (zh) | 2012-04-18 |
| CR9031A (es) | 2009-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7956063B2 (en) | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile | |
| IL181650A (en) | Solid pharmaceutical composition comprising a pharmaceutically acceptable carrier and hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile and use thereof in the manufacture of a medicament for treating or preventing hiv infection | |
| KR101524165B1 (ko) | Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법 | |
| KR101284361B1 (ko) | 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드 | |
| ZA200701826B (en) | Furamate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl] amino]-2-pyrimidinyl]amino]benzonitrile | |
| US8101629B2 (en) | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile | |
| US20180116964A1 (en) | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile | |
| AU2005279157B2 (en) | Fumarate of 4-[[4-[[4- (2-cyanoethenyl) -2,6-dimethylphenyl]amino)-2-pyrimidinyl)amino]benzonitrile | |
| JP2001502338A (ja) | 感染性疾患に対する化合物及び方法 | |
| HK1112862B (en) | Furamate of 4-((4-(4-(2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile | |
| NZ553322A (en) | Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile, also named TMC278 | |
| NZ553323A (en) | Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile, also named TMC278 |